Antisoma drug flunks ovarian cancer trial

The UK's Antisoma says that its experimental therapy for ovarian cancer has failed a clinical trial, triggering a swift loss of about one fifth of the company's share value. The mid-stage trial of ASA404 showed no increase in time to tumor progression when added to chemotherapy. Antisoma still has high hopes, though, that the therapy will prove convincingly effective against lung cancer. Novartis, which inked an $890 million pact on the drug in April, is preparing a Phase III study. "Based on these data, development in ovarian cancer will not be a priority," Antisoma said in a statement.

- see the release
- read the report on the trial results from MarketWatch

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.